化疗联合 DC－CIK 治疗晚期胃癌疗效及对免疫功能的影响

摘要

Objective It is to observe the clinical efficacy of chemotherapy combined with DC -CIK on the patients with advanced gastric cancer and its influence on the immune function .Methods 180 patients with advanced gastric cancer were randomly divided into observation group (90 cases) and control group (90 cases).Two groups of patients were treated with chemotherapy (oxaliplatin +5-fluorouracil), and plus DC-CIK treatment of self-immune cells on the basic of chemothera-py in observation group .The clinical efficacy , adverse reactions , immune function were observed before and after treatment in two groups.Results After treatment, the disease control rate of the observation group was significantly higher than that of the control group (P<0.05), and the incidence of bone marrow suppression was significantly lower than that of the control group (P<0.05), there was no significant difference in the incidence of fever , chills combined fever, rash in the two groups (P>0.05).After treatment, the levels of IL -12, IFN-γin the peripheral blood were higher in the observation group ( P<0.05) but lower in the control group than before treatment ( P <0.05 ); the levels of CD3 +, CD8 +, CD56 +/CD3 +, CD16 +/CD3 +, IgG, IgM, IgA in peripheral blood were increased (P<0.05) but CD4 +and CD4 +/CD8 +lower than before treatment in the observation group (P<0.05), however, the levels of CD3 +, CD8 +, CD56 +/CD3 +, CD16 +/CD3 +, IgG, IgM, IgA, IL-12, IFN-γin peripheral blood were lower but CD 4 +and CD4 +/CD8 +were higher than before treatment in the control group (all P<0.05).Conclusion Chemotherapy combined with DC -CIK can improve the immune function, and increase the disease control rate , and with little adverse reactions .%目的：观察化疗联合DC－CIK治疗晚期胃癌的疗效及对免疫功能的影响。方法将180例诊断为晚期胃癌的患者随机分为观察组90例与对照组90例。2组均给予奥沙利铂＋5－氟尿嘧啶化疗，观察组在化疗基础上给予DC－CIK免疫细胞治疗，统计2组治疗后的临床疗效、不良反应发生情况，检测治疗前后免疫功能及血清细胞因子IL－12、IFN－γ水平。结果治疗后观察组疾病控制率明显高于对照组（P＜0．05），骨髓抑制发生率明显低于对照组（P＜0．05），2组发热、高热伴寒战、皮疹发生率比较差异无统计学意义。治疗后观察组外周血CD3＋、CD8＋、CD56＋／CD3＋、CD16＋／CD3＋、IgG、IgM、IgA及IL－12、IFN－γ水平均明显高于治疗前及对照组（ P均＜0．05）， CD4＋、CD4＋／CD8＋均明显低于治疗前及对照组（P均＜0．05）；而对照组外周血CD3＋、CD8＋、CD4＋／CD8＋、CD56＋／CD3＋、CD16＋／CD3＋、IgG、IgM、IgA及IL－12、IFN－γ水平均明显低于治疗前（P均＜0．05），CD4＋、CD4＋／CD8＋均明显高于治疗前（P均＜0．05）。结论化疗联合DC－CIK能改善晚期胃癌患者的免疫功能，提高疾病控制率，且不良反应较少。